Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
11/2005
11/10/2005WO2005105778A2 4-amino-5-cyanopyrimidine derivatives
11/10/2005WO2005105771A1 Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
11/10/2005WO2005105769A2 Mycophenolate mofetil impurity
11/10/2005WO2005105763A1 Substituted morpholine compounds for the treatment of central nervous system disorders
11/10/2005WO2005105760A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005WO2005105748A1 4-halogenalkylpyridin-3-sulphonamides, method for producing same, agents containing same, and use thereof as agents for pest control
11/10/2005WO2005105743A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof
11/10/2005WO2005105739A2 Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
11/10/2005WO2005105735A1 Phenoxyacetic acid derivatives as ppar agonists
11/10/2005WO2005105100A1 Morpholine compounds
11/10/2005WO2005105079A2 Novel imidazoles
11/10/2005WO2005082858A3 Isoquinoline derivatives
11/10/2005US20050250829 Kinase inhibitors
11/10/2005US20050250826 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
11/10/2005US20050250825 peroxisome proliferator activated receptor modulators; diabetes mellitus; side effects reduction; 2-Methyl-2-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}propionic acid; Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis
11/10/2005US20050250824 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient
11/10/2005US20050250816 Positive allosteric modulators of the nicotinic acetylcholine receptor
11/10/2005US20050250815 e.g. 4-Methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
11/10/2005US20050250813 Injectable depot formulation comprising crystals of iloperidone
11/10/2005US20050250797 Quinzoline derivatives for use in the treatment of cancer
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250784 1-(2-naphthylsulfonyl)-4-(5-hydroxyaminocarbonylthiazol-2-yl)piperazine;antiprolifrative agent; cell cycle arrest, cellular differentiation, apoptosis and reversal of the transformed phenotype;
11/10/2005US20050250782 Heterocyclic inhibitors of MEK and methods of use thereof
11/10/2005US20050250775 Novel compounds
11/10/2005US20050250774 N-{2-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-6-morpholin-4-yl-pyridin-4-yl}-N'-(1 H-indol-3-ylmethylene)-hydrazine; interleukin IL-12 overproduction-related disorder; antiinflammatory agent; autoimmune diseases: multiple sclerosis, sepsis, neuropathies, cirrhosis, hepatitis, diabetes, arthritis
11/10/2005US20050250773 Reacting mycophenolic acid with C1 to C 4 alcohol or 4-(2-hydroxyethyl)morpholine in presence of catalyst; solvent-free; extraction; crystallization
11/10/2005US20050250770 Fused heterocyclic compounds
11/10/2005US20050250761 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis
11/10/2005US20050250707 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
11/10/2005US20050249668 Nir-fluorescent cyanine dyes, their synthesis and biological use
11/10/2005DE102004019492A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/10/2005CA2564994A1 Substituted morpholine compounds for the treatment of central nervous system disorders
11/10/2005CA2564085A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005CA2563222A1 Novel imidazoles
11/10/2005CA2563063A1 Purification of progesterone receptor modulators
11/10/2005CA2562160A1 Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
11/10/2005CA2555461A1 Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
11/09/2005EP1592686A1 Gyrase inhibitors and uses thereof
11/09/2005EP1592675A2 Crystalline modifications of triazinylaminostilbenes
11/09/2005EP1501787B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists
11/09/2005EP1320611B1 Heterologous production of polyketides
11/09/2005EP1095016B1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
11/09/2005EP0979226B1 Isoxazole derivatives
11/09/2005EP0966440B1 Method of production and method of separation of 2,4'-dipyridyl derivatives and methods of production of benzoxazepine derivatives and salts thereof
11/09/2005CN1694880A 6-methylpyridine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
11/09/2005CN1694876A Dibenzoxazepine
11/09/2005CN1694873A Vanilloid receptor ligands and their use in treatments
11/09/2005CN1694708A Inhibitors of tgfbeta
11/09/2005CN1694704A Use of (1H-benzimidazole-2-yl)-(piperazineyl)- ketaderavitive and correlative compound used as histamine H4 receptor antagonist for the treatment of allergy and asthma
11/09/2005CN1226297C Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
11/08/2005US6962935 Anticoagulants; thrombosis therapy; cardiovascular disorders
11/08/2005US6962932 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
11/08/2005US6962923 Pyrazole compositions
11/08/2005US6962917 E.g., (R)-2-(4-((4-fluoro-1H-benzimidazol-2-ylmethyl)-amino)-piperidin-1-yl)-1-(6- methoxyquinolin-4-yl)-ethanol; effective against both gramnegative and grampositive bacteria
11/08/2005CA2249222C Aminopyridine derivatives
11/08/2005CA2195677C Endothelin antagonists
11/03/2005WO2005103044A1 Pyrazole sulfonylurea compound and herbicide
11/03/2005WO2005103043A1 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer’s disease
11/03/2005WO2005103042A1 Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
11/03/2005WO2005103041A2 Treatment of cns disorders using cns target modulators
11/03/2005WO2005103037A2 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
11/03/2005WO2005103030A1 1,4-di substituted benzene compounds, process for preparing the same and use thereof
11/03/2005WO2005103020A1 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
11/03/2005WO2005103019A1 Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
11/03/2005WO2005103000A1 N-`4-4(4-morpholinyl) phenyl!-`(4-piperidinyl) methyl! carboxamide derivatives and their use as glycine transporter inhibitors
11/03/2005WO2005102998A1 Novel androgens
11/03/2005WO2005101989A2 Piperidine derivatives as modulators of chemokine receptor ccr5
11/03/2005WO2005070890A3 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
11/03/2005WO2004096131A3 Inhibitors of akt activity
11/03/2005WO2002004440A9 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
11/03/2005US20050245596 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
11/03/2005US20050245595 Positive modulators of nicotinic receptor agonists
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245585 Process for preparing optically pure zolmitriptan
11/03/2005US20050245584 Peroxisome proliferator activated receptor agonists
11/03/2005US20050245581 3-(2-Cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; antagonists of AMPA and kainate receptors; neuroprotectants; neurodegenerative diseases; Alzheinmer's disease; antiepileptic agents; antispasmodic agents; anxiolytic agents; ddrug abuse; nervous sytem disorders; antihypoxic agents
11/03/2005US20050245580 Novel substituted dihydro 3-halo-1H-pyrazole-T-carboxylates, their preparation and use
11/03/2005US20050245576 Substituted pyrazoles
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245552 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
11/03/2005US20050245551 Amide derivatives
11/03/2005US20050245547 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma
11/03/2005US20050245538 Dipeptidyl peptidase inhibitor; antidiabetic agents; obesity; viricides; anticancer agents; oral diseases; autoimmune disease
11/03/2005US20050245530 Monocyclic heterocycles as kinase inhibitors
11/03/2005US20050245527 Nitrogen containing heterocyclic compounds and medicines containing the same
11/03/2005US20050245526 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
11/03/2005US20050245521 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation
11/03/2005US20050245519 Substituted morpholine compounds for the treatment of central nervous system disorders
11/03/2005US20050245515 Indolyl derivatives as liver-X-receptor (LXR) modulators
11/03/2005US20050245513 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
11/03/2005US20050245500 Beta-ketoamide compounds with MCH antagonistic activity
11/03/2005US20050245432 N-methyl amino acids
11/03/2005US20050244718 Polymerizable, luminescent compounds and mixtures, luminescent polymer materials and their use
11/03/2005CA2565219A1 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
11/03/2005CA2563826A1 Treatment of cns disorders using cns target modulators
11/03/2005CA2563639A1 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer~s disease
11/03/2005CA2563615A1 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
11/03/2005CA2562571A1 Novel androgens
11/03/2005CA2562417A1 Piperidine derivatives as modulators of chemokine receptor ccr5
11/03/2005CA2558741A1 Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
1 ... 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 ... 647